Evercore Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $5
ProQR Therapeutics Price Target Announced at $5.00/Share by Evercore ISI Group
ProQR Therapeutics Analyst Ratings
Evercore Initiates ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $5
JMP Securities Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $8
ProQR Therapeutics Price Target Maintained With a $4.00/Share by Chardan Capital
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
ProQR Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12
JMP Securities Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $8
Citi Upgrades ProQR Therapeutics(PRQR.US) to Buy Rating, Raises Target Price to $4
ProQR Therapeutics Upgraded to Buy From Neutral at Citi
ProQR Therapeutics Analyst Ratings
JonesTrading Initiates ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $11
ProQR Therapeutics Initiated With a Buy at JonesResearch
JMP Securities Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $8
JMP Securities Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $8
Oppenheimer Initiates ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $15
Oppenheimer Initiates ProQR Therapeutics at Outperform With $15 Price Target
Chardan Capital Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $4